Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P0DP57

UPID:
SLUR2_HUMAN

ALTERNATIVE NAMES:
Secreted LY6/PLAUR domain-containing protein 2; Secreted Ly-6/uPAR-related protein 2

ALTERNATIVE UPACC:
P0DP57; D3DWI7; G3XAC2; Q86SR0; Q9BZG9

BACKGROUND:
The protein Secreted Ly-6/uPAR domain-containing protein 2, with alternative names Secreted LY6/PLAUR domain-containing protein 2 and Secreted Ly-6/uPAR-related protein 2, is identified for its binding and modulation of acetylcholine receptors. Its activity includes the inhibition of ACh-evoked currents in nAChRs and modulation of mAChRs, indicating its significant role in neurotransmission and cellular signaling.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Secreted Ly-6/uPAR domain-containing protein 2 offers a promising avenue for the development of novel therapeutic approaches, especially in diseases where acetylcholine receptor regulation is crucial.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.